Antidepressant drugs and cytokines in mood disorders

International Immunopharmacology

Volumn 2, Issue 12, 2002, Pages 1619-1626

  Nishida, Akira ^a   Hisaoka, Kazue ^a   Zensho, Hidenobu ^a   Uchitomi, Yousuke ^b   Morinobu, Shigeru ^c   Yamawaki, Shigeto ^c  

^a National Hospital Organization   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Antidepressant; Bipolar disorder; Cytokine; Depression; Interferon; Interleukin; Mood disorder; Sickness behavior

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOKINE; FLUOXETINE; LITHIUM; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR;

BEHAVIOR; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; ELECTROENCEPHALOGRAM; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; MOOD; MOOD DISORDER; NEUROCHEMISTRY; NEUROENDOCRINOLOGY; NEUROIMMUNOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; ANIMAL; IMMUNE SYSTEM; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYTOKINES; HUMANS; IMMUNE SYSTEM; LITHIUM; MONOAMINE OXIDASE INHIBITORS; MOOD DISORDERS;

EID: 0036843833     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00190-X     Document Type: Review

References (45)

1. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron. 34:2002 March 28;13-25.
2. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 19:1995;11-38.
3. Müller N., Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;1-33.
4. Dantzer R., Wollman E.E., Yirmiya R. Cytokines, stress, and depression. Adv. Exp. Med. Biol. vol. 461:1999;Plenum, New York.
5. Dantzer R., Wollman E.E., Vitkovic L., Yirmiya R. Cytokines and depression: fortuitous or causative association? Mol. Psychiatry. 4:1999;328-332.
6. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry. 157:2000;683-694.
7. Leonard B.E. The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;767-780.
8. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 25:2002;154-159.
9. Szelényi J. Cytokines and the central nervous system. Brain Res. Bull. 54:2001;329-338.
10. Levine J., Barak Y., Chengappa K.N., Rapoport A., Rebey M., Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 40:1999;171-176.
11. Levine J., Barak Y., Chengappa K.R., Rapoport A., Antelman S.M., Barak V. Low CSF soluble interleukin 2 receptor levels in acute depression. Short communication J. Neural Transm. 106:1999;1011-1015.
12. Neveu P.J., Castanon N. Is there evidence for an effect of antidepressant drugs on immune function? Adv. Exp. Med. Biol. 461:1999;267-281.
13. Weizman R., Laor N., Podliszewski E., Notti I., Djaldetti M., Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. Biol. Psychiatry. 35:1994;42-47.
14. Sluzewska A., Rybakowski J.K., Laciak M., Mackiewicz A., Sobieska M., Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N. Y. Acad. Sci. 762:1995;474-476.
15. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 22:2000;370-379.
16. Kagaya A., Kugaya A., Takebayashi M., Fukue-Saeki M., Saeki T.et al. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology. 43:2001;59-62.
17. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E.et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34:1995;301-309.
18. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 9:1997;853-858.
19. Anisman H., Ravindran A.V., Griffiths J., Merali Z. Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol. Psychiatry. 46:1999;1649-1655.
20. Goldman L.S. Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics. 35:1994;412-413.
21. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S.et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344:2001;961-966.
22. Mohr D.C., Goodkin D.E., Likosky W., Gatto N., Baumann K.A., Rudick R.A. Treatment of depression improves adherence to interferon beta-1β therapy for multiple sclerosis. Arch. Neurol. 54:1997;531-533.
23. Xia Z., DePierre J.W., Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology. 34:1996;27-37.
24. Maes M., Song C., Lin A.H., Bonaccorso S., Kenis G.et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 20:1999;370-379.
25. Kubera M., Kenis G., Bosmans E., Scharpe S., Maes M. Effects of serotonin and serotonergic agonists and antagonists on the production of interferon-gamma and interleukin-10. Neuropsychopharmacology. 23:2000;89-98.
26. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M.et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry. 58:2001;445-452.
27. Kubera M., Symbirtsev A., Basta-Kaim A., Borycz J., Roman A.et al. Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol. J. Pharmacol. 48:1996;503-506.
28. Kubera M., Simbirtsev A., Mathison R., Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res. 96:2000;255-66.4.
29. Kubera M., Holan V., Mathison R., Maes M. The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology. 25:2000;785-797.
30. Kubera M., Maes M., Holan V., Basta-Kaim A., Roman A., Shani J. Prolonged desipramine treatment increases the production of interleukin-10, an anti-inflammatory cytokine, in C57BL/6 mice subjected to the chronic mild stress model of depression. J. Affect. Disord. 63:2001;171-178.
31. Suzuki E., Shintani F., Kanba S., Asai M., Nakaki T. Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain. Neurosci. Lett. 215:1996;201-204.
32. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 711:1996;163-174.
33. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H.et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology. 24:2001;531-544.
34. Castanon N., Bluthe R.M., Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl.). 154:2001;50-60.
35. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A.et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1:1995;244-248.
36. Shen Y., Connor T.J., Nolan Y., Kelly J.P., Leonard B.E. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci. 65:1999;1773-1786.
37. Dunn A.J., Swiergiel A.H. The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment. Neuroimmunomodulation. 9:2001;163-169.
38. Rapaport M.H., Guylai L., Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J. Psychiatr. Res. 33:1999;335-340.
39. Rapport M.H., Manji H.K. The effects of lithium on ex vivo cytokine production. Biol. Psychiatry. 50:2001;217-224.
40. Maes M., Song C., Lin A.H., Pioli R., Kenis G.et al. In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology (Berl.). 143:1999;401-407.
41. Lin A., Song C., Kenis G., Bosmans E., De Jongh R.et al. The in vitro immunosuppressive effects of moclobemide in healthy volunteers. J. Affect. Disord. 58:2000;69-74.
42. Dunn A.J., Wang J., Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv. Exp. Med. Biol. 461:1999;117-127.
43. Duman R.S., Malberg J., Thome J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry. 46:1999;1181-1191.
44. Vitkovic L., Bockaert J., Jacque C. "Inflammatory" cytokines: neuromodulators in normal brain? J. Neurochem. 74:2000;457-471.
45. Inui A. Cytokines and sickness behavior: implications from knockout animal models. Trends Immunol. 22:2001;469-473.